- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00659334
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
Multi-disciplinary Study: MR, Histologic and EM Imaging of Intravenous Superparamagnetic Crystalline Particles (Combidex) to Brain, Intra-cerebral Tumors and in CNS Inflammation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects are recruited as patients in one of the neurology, neurosurgery or neuro-oncology clinics at OHSU. There are four groups of the study:
- Subjects receive the combidex infusion only.
- Subjects receive Combidex and undergo a previously schedule neurosurgery.
- Subjects undergo surgery only and provide a sample of their tumor tissue to be used in pathology studies of Combidex.
- Subjects with MS or stroke are invited to participate in receiving Combidex to evaluate the effectiveness of enhancing the area of damage within the brain.
Subjects are deemed eligible for the study and undergo a baseline MRI within 28 days of receiving Combidex. Subjects receiving Combidex are admitted for a half day into the Oregon Clinical & Translational Research Institute(OCTRI). Combidex is infused I.V. over 30 minutes. Subjects are monitored for side effects and are discharged within about 5 hours after the infusion, if no complications have been noted. Subjects return 24 hours after the infusion for a post infusion MRI scan and return again to one of the neurology clinics for one month follow-up. Subjects enrolled in group 2 undergo surgery 1-2 days after the Combidex infusion and also undergo a 24 post infusion MRI and return for one month follow-up. These subjects are also followed closely by the neurosurgical physician during the course of follow-up. Subjects enrolled in group 3 only undergo surgery and agree to have a piece of their tumor resection or biopsy donated for use in the study. Group 4 is the same as group 1, except the patient population includes multiple sclerosis and stroke instead of patients with brain tumors.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Brain tumor or CNS inflammatory lesion including stroke or MS
- 5 yrs old or older
- Able to undergo MRI without general anesthesia
- Agree to be followed for 1 month following infusion of Combidex
- Sign a written informed consent
- If female and of child-bearing potential, be postmenopausal, sterile, or be on birth control for 1 month prior to study
- Must have a pre-treatment MRI within 28 days before study
Exclusion Criteria:
- Clinically significant signs of uncal herniation
- Allergy to study drug, Combidex
- Hepatic insufficiency
- Stage IV or V renal insufficiency
- If female, pregnant or lactating
- Require anesthesia for MRI scanning
- Hemachromatosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Adults with brain tumor to receive Combidex infusion only
|
2.6 mg/kg
Other Names:
|
Active Comparator: 2
Adults with brain tumors to receive Combidex infusion and neurosurgery
|
2.6 mg/kg
Other Names:
neuro-surgical tumor biopsy or resection to assess particle localization.
Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v.
Combidex administration.
Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared.
The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
|
Other: 3
Adults with brain tumors to receive neurosurgery only (NO Combidex)
|
neuro-surgical tumor biopsy or resection to assess particle localization.
Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v.
Combidex administration.
Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared.
The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
|
Active Comparator: 4
Children with brain tumors to receive Combidex only
|
2.6 mg/kg
Other Names:
|
Active Comparator: 5
Children with brain tumors to receive Combidex and neurosurgery
|
2.6 mg/kg
Other Names:
neuro-surgical tumor biopsy or resection to assess particle localization.
Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v.
Combidex administration.
Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared.
The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
|
Other: 6
Children with brain tumors to receive neurosurgery only, NO Combidex
|
neuro-surgical tumor biopsy or resection to assess particle localization.
Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v.
Combidex administration.
Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared.
The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
|
Active Comparator: 7
Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
|
2.6 mg/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experience Optimal Imaging in Adult and Pediatric Brain Tumors to Establish Timing and Sequencing Parameters of Combidex.
Time Frame: 24 hours (some patients between 3 and 72 hours) after administration of Combidex
|
Signal intensity change in participants with Pre and 24 hours Post Combidex on T1, T2, T2* MRI sequences will be assessed (some patients undergo scans at 3 and 72 hours in order to assess radiographic changes at these time points).
Combidex will be administered in dose 2.6 mg/kg in adults with high and low grade gliomas, metastases, meningiomas, and PNET; and in pediatric patients with astrocytomas grade i-iv, brain stem gliomas, ependymomas, CNS germ cell tumors, and PNET.
|
24 hours (some patients between 3 and 72 hours) after administration of Combidex
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the Cellular Uptake of Particles in Brain Tumor Patients by Comparing Imaging Results With Histology and Electron Microscopic Examination of Biopsy Tissue
Time Frame: 2 years
|
2 years
|
Compare Combidex Imaging in Brain Tumor Patients, With Other CNS Inflammatory Lesions Such as Multiple Sclerosis and Stroke.
Time Frame: 2 years
|
2 years
|
Compare Pre- and Post-op Gd Enhanced MRI Combidex Enhanced MR Imaging Done Pre-, Intra- and Post-operatively, to Assess the Degree of Resection and Residual Tumor.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Edward A Neuwelt, MD, Oregon Health and Science University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00001127
- 5R01NS034608 (U.S. NIH Grant/Contract)
- OHSU-1127 (Other Identifier: OHSU IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Neoplasms
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
Constantinos HadjipanayisNational Cancer Institute (NCI); NX PharmaGenWithdrawnGlioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditionsUnited States
-
Vanderbilt University Medical CenterUniversity of Alabama at Birmingham; Emory University; H. Lee Moffitt Cancer... and other collaboratorsTerminatedBrain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Neoplasm, PrimaryUnited States
-
BioNumerik Pharmaceuticals, Inc.Crown BioscienceCompletedBrain Neoplasms | Brain Tumors | Malignant Neoplasms, BrainUnited States
-
National Cancer Institute (NCI)TerminatedCentral Nervous System Neoplasms | Brain Cancer | Neoplasms, Brain | Primary Brain Neoplasms | Cancer of the BrainUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Mayo ClinicRecruitingBrain Tumor | Brain Tumor Adult | Brain LesionUnited States
Clinical Trials on Ferumoxtran-10 (Combidex)
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknownProstatic Neoplasms | Lymphatic MetastasisNetherlands
-
Radboud University Medical CenterUnknown
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)Completed
-
Saving Patients' Lives Medical B.V.Radboud University Medical Center; ABX-CRO advanced pharmaceutical services... and other collaboratorsRecruitingProstate Cancer | Metastasis | ProstatectomyGermany, Netherlands, Belgium, Switzerland
-
M.D. Anderson Cancer CenterTerminatedProstate Cancer | Bladder Cancer | Genitourinary CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Endometrial Clear Cell Carcinoma | Stage III Endometrial Carcinoma | Cervical... and other conditionsUnited States, Korea, Republic of, Japan, Canada
-
Radboud University Medical CenterAstellas Pharma Inc; Catharina Ziekenhuis Eindhoven; Canisius-Wilhelmina HospitalUnknownProstate Cancer | Lymph Node MetastasesNetherlands
-
Ministry of Health and Population, EgyptCompletedPainful Diabetic NeuropathyEgypt
-
Celularity IncorporatedCompletedDiabetic Foot | Peripheral Arterial DiseaseUnited States